ELTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Elicio Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.55−0.01 (-0.64%)
Close on Oct 19, 2026
- Market cap
- $29.83M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Gross margin
–
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 146.9% | 817.9% | |
| Return on assets | – | – | -146.5% | |
| Current ratio | – | 0.39 | 2.38 | |
| Debt to equity | – | -0.01 | 5.75 | |
| Interest coverage | – | – | -33.3× | |
| Capex to revenue | – | 1.4% | – | |
| Diluted shares | – | 0M | 15M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Elicio Therapeutics generated $181.54M from operations and spent $1.36M on capital expenditure, dividends and share buybacks. 89% of that went back into the business.
Generated
$181.54M
Used
$1.36M
Capital expenditure$1.21M89%Dividends$00%Share buybacks$150.00K11%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-1225.9%
×Asset turnover0.04×
×Equity multiplier-0.67×
=Return on equity, FY202231.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2022 | -1225.9% | 0.04× | -0.67× | 31.9% |
| FY2021 | -192.8% | 0.39× | -0.87× | 66.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$39.57M
- Cash generatingOperating cash flow above zero-$36.95M
- Return on assets improvedROA up on the prior year-191.2% → -140.4%
- Earnings backed by cashOperating cash flow above net income-$36.95M vs -$39.57M
- Less leverageLong-term debt to assets fell71.1% → 36.4%
- Better liquidityCurrent ratio rose1.80 → 2.38
- No dilutionShare count did not rise12M → 15M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –